SCHEMBL18757474

SCHEMBL18757474

Cc1ccc(NC(=O)OC(C)(C)C)cc1NS(=O)(=O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.48
CYP2C9 P11712 2/20 0.48
GAA P10253 3/20 0.47
GFER P55789 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
HTT P42858 3/20 0.46
ALDH1A1 P00352 3/20 0.46
ALOX15 P16050 2/20 0.45
HSD17B10 Q99714 2/20 0.45
NR1H2 P55055 1/20 0.45
IDH1 O75874 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CYTH2 Q99418 1/20 0.45
GPR27 Q9NS67 1/20 0.45
MCL1 Q07820 1/20 0.45
MEN1 O00255 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17526213 0.87 HSP90AA1 (0.49) TSHRGAAGFERAPOBEC3GHTT
SCHEMBL30306582 0.87 HSP90AA1 (0.49) TSHRGAAGFERAPOBEC3GHTT
SCHEMBL7079519 0.83 MEN1 (0.58) GAAGFERALDH1A1HSD17B10NR1H2
SCHEMBL7079521 0.81 SMN1; SMN2 (0.52) TSHRCYP2C9GAAHTTALDH1A1
SCHEMBL20865561 0.80 ALDH1A1 (0.56) GAAALDH1A1MEN1KMT2ACA12
SCHEMBL22113057 0.80 KMT2A (0.49) GAAGFERAPOBEC3GALDH1A1NR1H2
SCHEMBL4016652 0.79 MAPT (0.54) HTTALDH1A1IDH1SMN1; SMN2MEN1
SCHEMBL18677862 0.78 CA12 (0.51) GAAALDH1A1MEN1KMT2ACA12
SCHEMBL18757898 0.78 CA12 (0.44) ALDH1A1MEN1KMT2ACA12CA1
SCHEMBL31173043 0.77 CA12 (0.52) GAAALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017066428-A1 BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) 2017-04-20 WO disclosed